Core Viewpoint - Sernova Biotherapeutics has appointed Ross Haghighat as Chair of the Board, emphasizing the company's commitment to advancing its innovative therapies for Type 1 diabetes [1][2][3] Company Developments - The company will complete its corporate jurisdiction continuance into British Columbia, transitioning from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) [4] - Sernova has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc. to better reflect its business focus, with no changes expected in its ticker symbols [5] Leadership Insights - Ross Haghighat brings over three decades of experience in healthcare technology ventures, which will support Sernova's strategic direction and innovation objectives [2][3] - The Board of Directors has expressed unanimous support for Mr. Haghighat's appointment, highlighting confidence in his leadership [3] Product Focus - Sernova is developing a Cell Pouch bio-hybrid organ aimed at providing a functional cure for Type 1 diabetes, integrating human donor cells or stem cells to replicate or enhance organ function [6] - The innovative approach of creating a bio-hybrid organ aims to deliver revolutionary treatments for chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders [6]
Sernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova Biotherapeutics